MF Clinical Trials

4 recruiting

MF Trials at a Glance

85 actively recruiting trials for mf are listed on ClinicalTrialsFinder across 6 cities in 39 countries. The largest study group is Not Applicable with 33 trials, with the heaviest enrollment activity in Tianjin, Houston, and Beijing. Lead sponsors running mf studies include Brien Holden Vision Institute, The University of Sydney, and Chengdu Zenitar Biomedical Technology Co., Ltd.

Browse mf trials by phase

Treatments under study

About MF Clinical Trials

Looking for clinical trials for MF? There are currently 4 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new MF trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about MF clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 85 trials

Recruiting
Phase 1

A Phase 1 Study of PRT12396 in Participants With Select Myeloproliferative Neoplasms

Myelofibrosis (MF)Polycythemia Vera (PV)Myeloproliferative Neoplasms (MPNs)
Prelude Therapeutics100 enrolled1 locationNCT07469891
Recruiting
Not Applicable

Exercise in Patients With Hypermobile Joints and Knee Pain

Hypermobility SyndromeKnee DiscomfortHypermobility, Joint
University of Southern Denmark90 enrolled2 locationsNCT06277401
Recruiting

Familial Mediterranean Fever and Related Disorders: Genetics and Disease Characteristics

FeverFamilial Mediterranean Fever (FMF)Autoinflammation+1 more
National Human Genome Research Institute (NHGRI)5,000 enrolled5 locationsNCT00001373
Recruiting
Phase 1Phase 2

A Study of Roginolisib in Combination With Ruxolitinib in Patients With Myelofibrosis (MF) Who Are Unresponsive to JAK Inhibitors

Myelofibrosis (MF)
iOnctura26 enrolled11 locationsNCT06887803
Recruiting
Not Applicable

The Impact of Image-Assisted Colonoscope on Patient Experience, Physician Workload, and Examination Quality

Colorectal Cancer ScreeningColonic Polyps/Colonoscopy/Colorectal NeoplasmsDifficult Colonoscopy+1 more
DONG WU200 enrolled1 locationNCT07541924
Recruiting
Not Applicable

Examining Olive Oil Extract on Knee Comfort and Function

Healthy Adult MaleJoint DiscomfortHealthy Adult Females
Applied Food Sciences Inc.168 enrolled1 locationNCT07514013
Recruiting
Phase 2

A Clinical Trial of Flonoltinib Maleate Tablets in the Treatment of JAK Inhibitor Refractory/Relapsed/Intolerant Patients With Medium to High Risk Myelofibrosis

MF
Chengdu Zenitar Biomedical Technology Co., Ltd64 enrolled2 locationsNCT07443306
Recruiting

Quality Improvement Project to Reduce Preoperative Fasting Times Before Elective Procedures

Preoperative FastingPostoperative Nausea and Vomiting (PONV)Perioperative Patient Comfort / Quality of Care
University of Giessen1,000 enrolled1 locationNCT07488468
Recruiting
Phase 2

Study of Canakinumab in Patients With Myelofibrosis

Primary MyelofibrosisPost-essential Thrombocythemia MyelofibrosisET-MF+2 more
John Mascarenhas14 enrolled8 locationsNCT05467800
Recruiting

Tolerance, Use and Performance of the PEASY Urine Collection Device in Hospitalized Patients

Urinary IncontinenceMedical Device Discomfort
Centre Hospitalier Universitaire de Nīmes20 enrolled1 locationNCT07028996
Recruiting
Phase 3

A Clinical Trial of Flonoltinib Maleate for Intermediate or High-Risk Myelofibrosis

MF
Chengdu Zenitar Biomedical Technology Co., Ltd105 enrolled2 locationsNCT07317700
Recruiting
Not Applicable

THE EFFECT OF REIKI ON BREASTFEEDING, PAIN AND COMFORT AFTER CESAREAN SECTION

Postpartum CarePostpartum ComfortBreastfeeding Self-Efficacy+5 more
Saglik Bilimleri Universitesi99 enrolled1 locationNCT07447609
Recruiting
Not Applicable

Assessing the Effects of Cool Roofs on Indoor Environments and Health

Sleep QualityDepressionDehydration+22 more
Aditi Bunker3,200 enrolled5 locationsNCT06579950
Recruiting
Not Applicable

Comparison of Outpatient Rehabilitation Versus Self-training for the Treatment and Prevention of Postpartum Pelvic Floor Dysfunction

Pelvic Floor DysfunctionPostpartum CarePostpartum Comfort+3 more
Vilnius University80 enrolled1 locationNCT07426770
Recruiting
Not Applicable

A New Diagnostic Algorithm to Non-invasively Track Fibrotic Changes in Myeloproliferative Neoplasms Based on C-C Chemokine Receptor 2 Detection. From Flow Cytometry to the Development of Targeted Positron Emission Tomography Molecular Imaging. Pre-clinical Studies and First In-human Proof of Concept

Myelofibrosis (MF)
Azienda Ospedaliero-Universitaria di Parma265 enrolled1 locationNCT07419178
Recruiting
Not Applicable

Evaluation of Gut-Related Well-Being and Mood Effects of a Daily Nutritional Food Ingredient From the Co-Fermentation of Fungal Mycelium (Pleurotus Pulmonarius) and Microalgae (Chlorella Vulgaris)

Gastrointestinal DiscomfortDigestive Well BeingGut-related Symptoms
Koralo GmbH80 enrolled1 locationNCT07407777
Recruiting
Phase 2

Hypofractionated, 3-week, Preoperative Proton or X-ray Radiotherapy for Patients With Localized Soft Tissue Sarcoma

Soft Tissue Sarcoma AdultLeiomyosarcomaSynovial Sarcomas+6 more
Oslo University Hospital110 enrolled4 locationsNCT07169344
Recruiting
Phase 1Phase 2

A First-in-Human, JAB-8263 in Adult Patients With Advanced Tumors

Ovarian CarcinomaNSCLCSCLC+5 more
Jacobio Pharmaceuticals Co., Ltd.152 enrolled1 locationNCT04686682
Recruiting
Phase 2

Reparixin in Patients With Myelofibrosis Myeloproliferative Neoplasms Research Consortium (MPN-RC 120)

Myelofibrosis (PMF)Post Essential Thrombocythemia Myelofibrosis (ET-MF)Post Polycythemia Vera Related Myelofibrosis (PV-MF)
Icahn School of Medicine at Mount Sinai26 enrolled9 locationsNCT05835466
Recruiting
Phase 1Phase 2

Phase I/II Clinical Trial of Axatilimab, a CSF1R Monoclonal Antibody, in Combination With Ruxolitinib as Therapy for Patients With Myelofibrosis (MF) and Chronic Myelomonocytic Leukemia (CMML)

Chronic Myelomonocytic Leukemia (CMML)Myelofibrosis (MF)
M.D. Anderson Cancer Center66 enrolled1 locationNCT07128381